Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An announcement from Dyadic International (DYAI) is now available.
Dyadic International, Inc. has struck a deal with Proliant Health and Biologicals to license its cutting-edge fungal production technology for manufacturing recombinant serum albumin. Dyadic stands to gain an initial $500,000, another half a million upon successful production strain transfer, and an additional $500,000 upon achieving a specified productivity level. Moreover, Dyadic will earn a share of the profits from Proliant’s sales of the animal-free product, marking a significant milestone in both companies’ commercial endeavors.
Find detailed analytics on DYAI stock on TipRanks’ Stock Analysis page.
